Prophylactic Use of Factor IX Concentrate in a Jehovah's Witness Patient

Annals of Thoracic Surgery

Volumn 88, Issue 5, 2009, Pages 1666-1668

  Bolliger, Daniel ^a   Sreeram, Gautam ^a   Duncan, Alexander ^a   Molinaro, Ross J ^a   Szlam, Fania ^a   Chen, Edward P ^a   Tanaka, Kenichi A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 9 COMPLEX; BLOOD CLOTTING FACTOR 9 CONCENTRATE; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBATE III; TRANEXAMIC ACID; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 9;

ADULT; AORTIC ARCH SURGERY; ARTICLE; BLEEDING; CASE REPORT; FEMALE; HEMODYNAMIC PARAMETERS; HUMAN; JEHOVAH'S WITNESS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SINGLE DRUG DOSE; HEMOSTASIS; MIDDLE AGED; THORACIC AORTA; VASCULAR SURGERY;

AORTA, THORACIC; BLOOD LOSS, SURGICAL; FACTOR IX; FEMALE; HEMOSTASIS, SURGICAL; HUMANS; JEHOVAH'S WITNESSES; MIDDLE AGED; VASCULAR SURGICAL PROCEDURES;

EID: 70449726980     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2009.03.095     Document Type: Article

References (9)

1. Sniecinski R., and Levy J.H. What is blood and what is not?. Caring for the Jehovah's Witness patient undergoing cardiac surgery. Anesth Analg 104 (2007) 753-754
2. Muramoto O. Bioethical aspects of the recent changes in the policy of refusal of blood by Jehovah's Witnesses. Br Med J 322 (2001) 37-39
3. Moskowitz D.M., Perelman S.I., Cousineau K.M., et al. Multidiciplinary management of a Jehovah's Witness patient for the removal of a renal cell carcinoma extending into the right atrium. Can J Anaesth 49 (2002) 402-408
4. Beholz S., Liu J., Thoelke R., Spiess C., and Konertz W. Use of desmopressin and erythropoietin in an anaemic Jehovah's Witness patient with severely impaired coagulation capacity undergoing stentless aortic valve replacement. Perfusion 16 (2001) 485-489
5. Sniecinski R.M., Chen E.P., Levy J.H., Szlam F., and Tanaka K.A. Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa. Anesth Analg 104 (2007) 763-765
6. Tanaka K.A., Waly A.A., Cooper W.A., and Levy J.H. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology 98 (2003) 1513-1515
7. Takabe K., Holman P.R., Herbst K.D., Glass C.A., and Bouvet M. Successful perioperative management of factor X deficiency associated with primary amyloidosis. J Gastrointest Surg 8 (2004) 358-362
8. Meng Z.H., Wolberg A.S., Monroe III D.M., and Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 55 (2003) 886-891
9. Bui J.D., Despotis G.D., Trulock E.P., Patterson G.A., and Goodnough L.T. Fatal thrombosis after administration of activated prothrombin complex concentrate in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 124 (2002) 852-854